Zobrazeno 1 - 10
of 179
pro vyhledávání: '"Anne-Marie Duliege"'
Autor:
Frederick W.K. Tam, James Tumlin, Jonathan Barratt, Brad H. Rovin, Ian S.D. Roberts, Candice Roufosse, H. Terence Cook, Gurjeet Bhangal, Alison L. Brown, Martin Busch, Fayaz Dudhiya, Anne-Marie Duliege, Donald J. Fraser, Daniel P. Gale, Chiu-Ching Huang, Ping-Chin Lai, Meng Lee, Esteban S. Masuda, Stephen P. McAdoo, Alexander R. Rosenkranz, Claudia Sommerer, Gere Sunder-Plassmann, Cheuk-Chun Szeto, Sydney C.W. Tang, Don E. Williamson, Lisa Willcocks, Volker Vielhauer, Min Jeong Kim, Leslie Todd, Hany Zayed, Sandra Tong-Starksen, Richard Lafayette
Publikováno v:
Kidney International Reports, Vol 8, Iss 12, Pp 2546-2556 (2023)
Introduction: We reported increased spleen tyrosine kinase (SYK) expression in kidney biopsies of patients with IgA nephropathy (IgAN) and that inhibition of SYK reduces inflammatory cytokines production from IgA stimulated mesangial cells. Methods:
Externí odkaz:
https://doaj.org/article/66982ca5bf66483cb14ee295eaf07526
Autor:
Lynn M. Matrisian, Manuel Hidalgo, Vincent J. Picozzi, Anirban Maitra, Anne-Marie Duliege, Diane M. Simeone, Andrew Eugene Hendifar, Regina Deck, Julie Fleshman, Gregory L. Beatty, Sudheer Doss
Publikováno v:
Cancer Research. 81:PO-050
Background: Drug development in PDAC has been disappointing with an extremely low trial success rate despite considerable effort. PrP is a transformative, adaptive clinical trial platform that attempts to correct this by continuously and rapidly eval
Autor:
Jiri Mayer, Anne-Marie Duliege, James B. Bussel, Hany Zayed, Michael Boxer, Sandra Tong, Nichola Cooper, Donald M. Arnold
Publikováno v:
American Journal of Hematology
Two randomized, double‐blind, placebo‐controlled studies demonstrated responses (≥50 000/μL) to fostamatinib in adults with long‐standing immune thrombocytopenia (ITP). The long‐term safety and efficacy of fostamatinib were evaluated in a
Autor:
Paul Eliezer Oberstein, Osama E. Rahma, Nina Beri, Amy C. Stoll-D'Astice, Anne-Marie Duliege, Emily Kawaler, Igor Dolgalev, Gregor Werba, Victoire Cardot-Ruffino, Naïma Böllenrücher, Saloney Nazeer, Matthew Squires, Dafna Bar-Sagi, Brian M. Wolpin, Stephanie Dougan, Diane M. Simeone
Publikováno v:
Journal of Clinical Oncology. 40:e16287-e16287
e16287 Background: Pancreatic ductal adenocarcinoma (PDA) has been refractory to therapeutic targeting of the immune microenvironment. In preclinical work, IL-1β was upregulated in PDA tumors, and in mouse models, IL-1β expression led to activation
Autor:
Vincent J. Picozzi, Anne-Marie Duliege, Eric Andrew Collisson, Anirban Maitra, Manuel Hidalgo, Andrew Eugene Hendifar, Gregory Lawrence Beatty, Sudheer Doss, Lynn McCormick Matrisian, Pamela S Herena, Julie Fleshman, Michelle A. Detry, Donald A. Berry, Diane M. Simeone
Publikováno v:
Journal of Clinical Oncology. 40:TPS4188-TPS4188
TPS4188 Background: The success rate of drug development in PDAC is disappointingly low.PrP is a transformative, adaptive platform clinical trial designed to continuously evaluate many novel therapeutic options while increasing the probability that p
Publikováno v:
Medical Research Archives. 9
Trends in clinical trials for pancreatic cancer between 2011-2020 were tracked in the Pancreatic Cancer Action Network database originally designed to assist in identifying open trials for eligible patients. More than 125 trials specific for pancreat
Autor:
Amit Sharma, Whedy Wang, Alex Yang, Ali Hariri, Hong-Ye Gao, Anne-Marie Duliege, Krishna Polu, Nina Oestreicher
Publikováno v:
Kidney Research and Clinical Practice, Vol 31, Iss 2, p A93 (2012)
Peginesatide (P) is a synthetic, pegylated, peptide-based ESA approved for treatment of anemia due to chronic kidney disease in adult patients (pts) on dialysis. P demonstrated noninferiority to epoetin (E) in maintenance of Hb levels in hemodialysis
Externí odkaz:
https://doaj.org/article/f0d82c6f1f414ed18f79fff23f4f1965
Autor:
Ali, McBride, Pratima, Nayak, Yuliya, Kreychman, Leslie, Todd, Anne-Marie, Duliege, Amit R, Mehta
Publikováno v:
The American journal of managed care. 25
Immune thrombocytopenia (ITP) is an autoimmune disease associated with substantial heterogeneity and varying outcomes. Significant bleeding, including intracranial hemorrhage, is a persistent risk for patients with ITP, along with cardiovascular dise
Autor:
PR Newswire
Publikováno v:
PR Newswire US. 03/08/2016.
Autor:
Waleed Ghanima, Brian Olender, Sandy Tong, Michael D. Tarantino, James B. Bussel, Robert P. Numerof, Leslie Todd, Yuliya Kreychman, Ralph V. Boccia, Anne-Marie Duliege, Michael Boxer, Quentin A. Hill, Nichola Cooper, Michelle Sholzberg
Publikováno v:
Blood. 134:1069-1069
Introduction. Immune thrombocytopenia (ITP) is characterized by autoantibody-mediated platelet destruction resulting in thrombocytopenia and often at least a degree of bruising and bleeding. Platelet destruction occurs within activated macrophages th